Gilead Sciences, Inc. (NASDAQ:GILD) BofA Securities 2023 Health Care Conference May 9, 2023 2:20 PM ET Company Participants Andy Dickinson - CFO Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the morning session of the BofA Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst. And we're thrilled today to have Gilead Sciences. And up on stage with me is Andy Dickinson. Andy, welcome. Andy Dickinson Thank you. Great to be here. Thanks for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdi ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2023 Earnings Conference Call April 27, 2023 4:30 AM ET Company Participants Jacquie Ross - VP, IR Daniel O'Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - CFO Conference Call Participants Dennis Ding - Jefferies Brian Abrahams - RBC Chris Schott - JPMorgan Geoff Meacham - Bank of America Terence Flynn - Morgan Stanley Umer Raffat - Evercore Tyler Van Buren - Cowen Hartaj Singh - Oppenheimer & C ...

Q123 Financial Results A p r i l 2 7 , 2 0 2 3 Forward-Looking Statements Statementsincludedinthispresentationthatarenothistoricalinnatureareforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995.Gileadcautions readersthatforward-lookingstatementsaresubjecttocertainrisksanduncertaintiesthatcouldcauseactualresultstodiffermaterially.Theserisksanduncertaintiesincludethoserelatingto:the impact of the COVID-19 pandemic on Gilead’s business, financial condition and results of ope ...

Gilead Sciences, Inc. (NASDAQ:GILD) Barclays 2023 Global Healthcare Conference March 15, 2023 10:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Carter Gould - Barclays Carter Gould Good morning, and welcome to day two of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst. I’m pleased to welcome Gilead to the major screen here. Merdad, if you probably can't see it or maybe you can, you're about 20 feet tall, you’re be ...

Gilead Sciences, Inc. (NASDAQ:GILD) Cowen 43rd Annual Healthcare Conference March 7, 2023 11:10 AM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Is this slide over? Is there an interference from the speaker? I guess it's just loud. All right. Well, again, good morning. Tyler Van Buren here Senior Biotech Analyst at TD Cowen. Thanks again for coming to TD Cowen's 43rd Annual Healthcare Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdiction of I ...

Summary of Gilead Sciences, Inc. Conference Call Company Overview - **Company**: Gilead Sciences, Inc. (NASDAQ:GILD) - **Date**: February 14, 2023 - **Event**: SVB Securities Global Biopharma Conference Key Points Company Position and Pipeline Development - Gilead has been adapting its pipeline over the past three years, focusing on sustainability and growth in HIV, virology, oncology, and inflammation [2][3] - The company has made significant progress through acquisitions and internal development, with products like remdesivir and Trodelvy [2] Trodelvy Insights - Trodelvy has received multiple approvals, including for triple-negative breast cancer and HR-positive/HER2-negative breast cancer, which are seen as underappreciated by the market [5][6] - The NCCN guideline update has elevated Trodelvy to category one, highlighting its importance in breast cancer treatment [5] - Gilead is expanding Trodelvy's indications into earlier treatment lines and non-small cell lung cancer, with ongoing studies to explore additional indications [7][8] Comparison with Competitors - Trodelvy's antibody-drug conjugate (ADC) technology differs from AstraZeneca's, particularly in linker and payload characteristics, which may affect efficacy and safety profiles [10][11] - Gilead's ADC has a hydrolyzable linker and a moderately toxic payload, which may lead to a more favorable safety profile compared to competitors [11][12] TIGIT Development - Gilead is optimistic about TIGIT's potential in combination with PD-1 inhibitors, showing promising progression-free survival (PFS) data [16][17] - The company is monitoring competitor developments closely, particularly Roche's trials, and believes that interim analyses should not be overinterpreted [18] Cell Therapy Leadership - Kite, Gilead's cell therapy division, maintains a leadership position with a high treatment success rate and reliable manufacturing processes [20] - Gilead is focused on optimizing CAR-T therapy delivery and exploring partnerships, including with Galapagos, to enhance its cell therapy offerings [21][22] Magrolimab and CD-47 Programs - Magrolimab is positioned for solid tumors and hematological malignancies, with ongoing Phase 3 trials expected to yield significant data [24][25] - Gilead is ahead in the CD-47 space, with multiple ongoing trials and a focus on safety and efficacy [26][27] COVID-19 Treatment Strategy - Gilead is conducting trials for its oral COVID treatment, with sample sizes of approximately 2,300 for high-risk and 1,900 for standard-risk patients [33][34] - The company acknowledges challenges in recruiting patients and the evolving nature of the pandemic but remains committed to advancing its treatment options [30][31] HIV Treatment Pipeline - Gilead has multiple molecules in development for HIV, aiming for long-lasting treatment options with improved tolerability [39][40] - The company is focused on presenting data on broadly neutralizing antibody combinations and other small molecule approaches [39][40] Inflammation Programs - Gilead's inflammation portfolio is in early stages, with key candidates like oral alpha4beta7 and IRAK4 programs expected to enter Phase 2 studies soon [42][43] - The company aims to develop first and best-in-class differentiated molecules for various inflammatory indications [44] Additional Insights - Gilead is committed to adapting its strategies based on evolving market conditions and patient needs, particularly in the context of the COVID-19 pandemic and competitive landscape [30][31][37] - The company emphasizes the importance of maintaining a robust pipeline and exploring new opportunities in both oncology and virology [2][3][40]

Gilead Sciences (GILD) Conference Summary Company Overview - Gilead Sciences is focusing on building a sustainable pipeline, particularly in HIV, virology, oncology, and inflammation [3][4] Key Products and Pipeline Trodelvy - Trodelvy has received approvals for triple-negative breast cancer and bladder cancer, with recent approval for HR positive HER2 negative breast cancer [5][6] - The strategy includes expanding indications and moving into earlier treatment lines, with ongoing studies in triple-negative and HR positive HER2 negative breast cancer, as well as non-small cell lung cancer [7][8] - Revenue trajectory for Trodelvy is positive, with expectations for continued growth [9] Non-Small Cell Lung Cancer - Comparison with AstraZeneca's TROP-two highlights differences in linker technology and payload, which may affect efficacy and safety profiles [10][11] - Gilead's hydrolyzable linker and moderately toxic payload are expected to provide a differentiated profile in lung cancer treatment [12][13] - Ongoing trials are similar in size and patient population to AstraZeneca's, but with key differences in patient selection criteria [15][16] TIGIT Development - Data presented at ASCO indicates that TIGIT adds value to PD-1 inhibitors in non-small cell lung cancer, with a promising PFS improvement [18][19] - Ongoing trials are designed to assess the efficacy of TIGIT in combination therapies [20][21] Cell Therapy - Kite, a Gilead subsidiary, is positioned as a leader in cell therapy, with a focus on optimizing CAR T technology and reducing delivery times [22][23] - Partnerships, including with Galapagos, are being leveraged to enhance cell therapy offerings [24][25] Magrolimab - Magrolimab is being developed for both solid tumors and hematological malignancies, with ongoing Phase III trials for MDS and AML [27][28] - The company is focused on safety and efficacy, with a patented dosing approach to minimize adverse effects [30][31] Oral COVID Treatment - Gilead is conducting trials for its oral COVID treatment, with sample sizes of approximately 2,300 for high-risk and 1,900 for standard-risk patients [37][38] - The company acknowledges challenges in recruiting patients and adapting to the evolving pandemic landscape [34][36] Lenacapavir and Inflammation Programs - Gilead is advancing multiple candidates in the inflammation space, including oral beta-seven, IRAK4, and TYPO2 programs, with Phase II studies expected in the next year or two [48][49] - The focus is on developing best-in-class differentiated molecules for various inflammatory indications [50] Additional Insights - Gilead is committed to adapting its strategies based on evolving market conditions and patient needs, particularly in the context of the COVID-19 pandemic and competitive landscape [34][36][41] - The company is actively monitoring and adjusting its clinical trial designs to ensure robust data collection and analysis [38][41] This summary encapsulates the key points discussed during the conference, highlighting Gilead's strategic focus, product pipeline, and ongoing developments in various therapeutic areas.

Financial Data and Key Metrics Changes - Full year 2022 sales of Biktarvy grew 20% year-over-year to $10.4 billion, exceeding $10 billion for the first time [8] - Total product sales for 2022 were $27 billion, flat compared to 2021, with growth in the base business offset by a decline in Veklury sales [14][39] - Non-GAAP diluted earnings per share was $1.67 in Q4 2022 compared to $0.69 in Q4 2021, impacted by a $0.25 charge from the termination of the Trodelvy collaboration [42] Business Line Data and Key Metrics Changes - HIV sales for Q4 2022 were $4.8 billion, a 5% year-over-year increase, driven by higher demand and favorable pricing dynamics [14] - Oncology sales, including Trodelvy, reached $680 million for the full year, up 79% year-over-year [23] - Cell therapy sales in Q4 were $490 million, up 75% year-over-year, driven by the uptake of Yescarta [25] Market Data and Key Metrics Changes - The U.S. PrEP market grew 18% year-over-year, with Descovy sales for Q4 at $537 million, up 13% year-over-year [15] - The overall HIV treatment market in the U.S. grew 1.5% year-over-year in Q4, with Europe seeing over 2% growth [15] - Veklury sales for 2022 totaled $3.9 billion, with Q4 sales at $1 billion, indicating a sustainable role in treating COVID-19 [22] Company Strategy and Development Direction - The company is focused on expanding its HIV portfolio and oncology business, with significant clinical progress expected in 2023 [7][9] - Gilead aims to enhance its market position with the recent approval of Sunlenca for multi-drug resistant HIV, targeting a small but significant patient population [20] - The company plans to continue investing in R&D, with expectations of 23 active Phase III trials by the end of 2023 [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the base business's growth trajectory, despite the expected decline in Veklury sales [50] - The company anticipates total product sales in 2023 to range from $26 billion to $26.5 billion, with base business growth projected at 4% to 6% [44] - Management highlighted the importance of maintaining a strong pipeline and adapting to market dynamics, particularly in the COVID-19 treatment landscape [68] Other Important Information - Non-GAAP product gross margin was 86.8%, up more than 16 percentage points from the previous year, primarily due to a legal settlement charge in 2021 [40] - The company returned over $5 billion to shareholders in 2022, including a 2.7% increase in quarterly cash dividends [47][48] Q&A Session Summary Question: Expectations for earnings growth in the next few years - Management indicated that while the base business is performing well, the impact of Veklury's decline complicates earnings projections, but they expect growth to accelerate in the long run as new products are introduced [50][51] Question: Expected dynamics for lenacapavir following approval - Management noted that lenacapavir targets a specific patient population, and while it's early days, they are optimistic about its potential and the response from physicians [54][55] Question: Differentiation of Trodelvy against competitors - Management emphasized their established market presence and the absence of significant safety issues in their development program, which they believe will support their competitive position [59] Question: Study design for Trodelvy in HR-positive, HER2-negative breast cancer - Management stated that they are still finalizing the study design and will share more details as they progress [62] Question: Confidence in the Fc-silent construct for TIGIT - Management expressed confidence based on clinical data from the ARC-7 trial, which demonstrated benefits of their approach compared to competitors [66]